PF-Atlas › Clinical Trials › NCT00463983
Treatment of Idiopathic Pulmonary Fibrosis With Long Acting Octreotide
octreotide · Phase 1
Registry ID
NCT00463983
Phase
Phase 1
Status
Completed
Drug / intervention
octreotide
Sponsor
Institut National de la Santé Et de la Recherche Médicale, France
Start
2006-10
Enrollment
25
Locations
16
About this trial
Octreotide is a somatostatin analog with a long half-life in vivo. Octreotide has interesting anti-inflammatory and anti-fibrotic properties in vitro and in vivo. Somatostatin receptors are increased and Octreotide uptake is increased in the lung in patients with idiopathic pulmonary fibrosis. Our hypothesis is that octreotide may slow the degradation of lung function in patients with IPF. In this proof of concept study, patients with IPF will receive an intramuscular injection of slow release octreotide (Sandostatin LP, 30 mg)every 4 weeks for 48 weeks. Lung function (FVC, DLCO), HRCT scores for fibrosis and ground glass, 6 minute walking test,quality of life and survival will be monitored.
Explore related
Medical disclaimer. This page summarizes public trial data for NCT00463983 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.